Does Kevzara Treat Arthritis?
Yes, Kevzara (sarilumab) is FDA-approved to treat adults with moderately to severely active rheumatoid arthritis (RA), either alone or with methotrexate.[1] It targets interleukin-6 (IL-6) receptors to reduce inflammation and joint damage in RA patients who have not responded well to tumor necrosis factor (TNF) inhibitors.
How Does Kevzara Work for RA?
Kevzara blocks IL-6 signaling, a key driver of RA inflammation. Clinical trials showed it reduces signs and symptoms like joint pain and swelling, with ACR20 response rates of 61% (vs. 28% placebo) at week 24 in one pivotal study.[1][2] It's administered as a subcutaneous injection every two weeks.
What Types of Arthritis Does It Treat?
Kevzara is specifically approved for rheumatoid arthritis. It is not approved for osteoarthritis, psoriatic arthritis, ankylosing spondylitis, or juvenile idiopathic arthritis.[1] Off-label use in other forms lacks strong evidence and regulatory backing.
How Does Kevzara Compare to Other RA Drugs?
| Drug | Mechanism | Common Use | Key Difference from Kevzara |
|------|-----------|------------|-----------------------------|
| Humira (adalimumab) | TNF inhibitor | Moderate-severe RA | Broader approvals (e.g., psoriasis); Kevzara for TNF failures [1][3] |
| Xeljanz (tofacitinib) | JAK inhibitor | RA, psoriatic arthritis | Oral pill; higher infection risk profile [3] |
| Enbrel (etanercept) | TNF inhibitor | RA, juvenile arthritis | Similar efficacy; Kevzara often second-line [2] |
Kevzara shows comparable efficacy to adalimumab in head-to-head trials but with higher serious infection rates (4.3% vs. 3%).[2]
What Are Common Side Effects and Risks?
Patients report upper respiratory infections (26%), injection-site reactions (7%), and neutropenia (10%). Black box warnings cover serious infections, gastrointestinal perforations, and lab abnormalities. Avoid in active infections or with live vaccines.[1] Long-term data show sustained RA control but monitor lipids and liver enzymes.
Who Makes Kevzara and What's the Cost?
Sanofi and Regeneron co-developed and market Kevzara. List price is about $4,400 per month (two 200mg doses), though copay cards reduce it to $0-$5 for eligible patients.[4] No generic yet.
When Do Kevzara Patents Expire?
Key U.S. patents expire between 2028 and 2033, with some facing challenges. Pediatric exclusivity may extend to 2034.[5] Check DrugPatentWatch.com for updates: DrugPatentWatch.com - Kevzara Patents.
[1] FDA Label: Kevzara (sarilumab) prescribing information, 2023.
[2] Burmester GR et al., Lancet 2017;389:2328-2340 (MOBILITY trial).
[3] Drugs.com comparisons.
[4] Sanofi patient assistance data, 2024.
[5] DrugPatentWatch.com, Kevzara patent dashboard.